Very expensive
Lani -
For those of us with the disease, this seems like a good idea.
We need a small molecule drug to pass the BBB, if they do not rework Herceptin.
However, I can see the insurance companies balking at the expense of two such drugs given together. Especially for any length of time, unless the patient is already known to have some mets to the brain.
Will be interesting to see if the other reasons for the RPLS will shed any new light on this rare side effect.
|